Список проголосовавших за комментарий " On The Wires<ul><li>Caladrius Biosciences, Inc. (<strong>CLBS</strong>) announced that three additional clinical sites, including UCSF Benioff Children's Hospital San Francisco, under the direction of investigator Stephen Gitelman, MD, have opened to enroll subjects for the Company's Phase 2 clinical trial of CLBS03 in type 1 diabetes, The Sanford Project: T-Rex Study. The other clinical sites include University of Florida Diabetes Institute and the Harold Schnitzer Diabetes Health Center at Oregon Health & Science University. These sites will contribute to the continued enrollment of subjects in the trial to meet the total of 111. The study is evaluating CLBS03 (the Company's product candidate consisting of autologous expanded regulatory T cells, or Tregs) as a treatment for recent-onset type 1 diabetes.</li><li>Orexigen Therapeutics (<strong>OREX</strong>) announced that Laboratorios Farmace´uticos Rovi has launched Mysimba in Spain.</li></ul>"